Home > Publications database > Detecting and Locating the Site of Local Relapse Using 18F-PSMA-1007 Imaging After Primary Treatment of 135 Prostate Cancer Patients-Potential Impact on PSMA-Guided Radiation Therapy. > print

001     181428
005     20240229145647.0
024 7 _ |a 10.1007/s11307-022-01766-6
|2 doi
024 7 _ |a pmid:35999425
|2 pmid
024 7 _ |a 1536-1632
|2 ISSN
024 7 _ |a 1860-2002
|2 ISSN
024 7 _ |a altmetric:134907525
|2 altmetric
037 _ _ |a DKFZ-2022-01996
041 _ _ |a English
082 _ _ |a 570
100 1 _ |a Koerber, S. A.
|0 P:(DE-HGF)0
|b 0
|e First author
245 _ _ |a Detecting and Locating the Site of Local Relapse Using 18F-PSMA-1007 Imaging After Primary Treatment of 135 Prostate Cancer Patients-Potential Impact on PSMA-Guided Radiation Therapy.
260 _ _ |a Cham
|c 2023
|b Springer Nature Switzerland
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1678876791_29492
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:E050# / 2023 Apr;25(2):375-383
520 _ _ |a Due to limited imaging options, the visualization of a local relapse of prostate cancer used to pose a considerable challenge. However, since the integration of 18F-PSMA-1007-PET/CT into the clinic, a relapsed tumor can now easily be detected by hybrid imaging. The present study aimed to evaluate and map the allocate relapse in a large cohort of prostate cancer patients focusing on individual patient management conclusions for radiation therapy.The current study included 135 men with prostate cancer after primary treatment who underwent 18F-PSMA-1007-PET/CT due to biochemical relapse detecting a local relapse. Imaging data were reassessed and analyzed with regard to relapse locations. For the correlation of tumor foci with clinical data, we used binary logistic regression models as well as the Kruskal-Wallis test and Mann-Whitney test.In total, 69.6% of all patients (mean age: 65 years) underwent prostatectomy while 30.4% underwent radiation therapy. PET imaging detected most frequently a unifocal relapse (72.6%). There was a statistically significantly higher rate of ipsilateral cases among the relapsed tumors. Comparing both treatment approaches, tumors relapsed most commonly within the posterior region after surgery and transition/peripheral zone after radiation therapy, respectively.The present study confirms that 18F-PSMA-1007-PET/CT is highly suitable for the localization and allocation of a local relapse in patients with prostate cancer. The data enable further optimizing dose prescriptions and target volume delineations of radiation therapy in the future.
536 _ _ |a 315 - Bildgebung und Radioonkologie (POF4-315)
|0 G:(DE-HGF)POF4-315
|c POF4-315
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a 18F-PSMA-1007
|2 Other
650 _ 7 |a Local relapse
|2 Other
650 _ 7 |a PET/CT
|2 Other
650 _ 7 |a PSMA
|2 Other
650 _ 7 |a Prostate cancer
|2 Other
700 1 _ |a Kroener, R. C.
|b 1
700 1 _ |a Dendl, K.
|b 2
700 1 _ |a Kratochwil, C.
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Fink, C. A.
|b 4
700 1 _ |a Ristau, J.
|b 5
700 1 _ |a Winter, E.
|b 6
700 1 _ |a Herfarth, K.
|b 7
700 1 _ |a Hatiboglu, G.
|b 8
700 1 _ |a Hohenfellner, M.
|b 9
700 1 _ |a Haberkorn, Uwe
|0 P:(DE-He78)13a0afba029f5f64dc18b25ef7499558
|b 10
|u dkfz
700 1 _ |a Debus, Jürgen
|0 P:(DE-He78)8714da4e45acfa36ce87c291443a9218
|b 11
|u dkfz
700 1 _ |a Giesel, F. L.
|b 12
773 _ _ |a 10.1007/s11307-022-01766-6
|0 PERI:(DE-600)2079211-6
|n 2
|p 375-383
|t Molecular imaging & biology
|v 25
|y 2023
|x 1536-1632
909 C O |p VDB
|o oai:inrepo02.dkfz.de:181428
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)13a0afba029f5f64dc18b25ef7499558
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-He78)8714da4e45acfa36ce87c291443a9218
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-315
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Bildgebung und Radioonkologie
|x 0
914 1 _ |y 2022
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2021-05-04
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-05-04
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-05-04
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b MOL IMAGING BIOL : 2022
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-08-22
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-08-22
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2023-08-22
920 1 _ |0 I:(DE-He78)E050-20160331
|k E050
|l E050 KKE Strahlentherapie
|x 0
920 1 _ |0 I:(DE-He78)E060-20160331
|k E060
|l E060 KKE Nuklearmedizin
|x 1
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 2
920 0 _ |0 I:(DE-He78)E050-20160331
|k E050
|l E050 KKE Strahlentherapie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)E050-20160331
980 _ _ |a I:(DE-He78)E060-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21